Epogen

(Epoetin Alfa)

ApprovedSmall molecule

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

This drug is used to treat anemia (low red blood cell counts) caused by kidney disease, chemotherapy, or certain medical treatments. It works by stimulating your body to produce more red blood cells, which helps prevent fatigue and the need for blood transfusions.[2] Epogen is currently approved and in use across 49 indications[4].[1]

Epogen is one of 1243 small molecule programs targeting Premature Birth. It is currently in Approved.

Indications

168

Total Trials

Active Trials

1,242

Competitors

Pipeline

Status by Indication[4][1]

Indication

Premature BirthActive, not recruiting

Blood TransfusionUnknown

HIV InfectionUnknown

NeutropeniaActive, not recruiting

Cardiac ArrestActive, not recruiting

Cerebral PalsyActive, not recruiting

Liver TransplantActive, not recruiting

Lung CancerActive, not recruiting

StrokeActive, not recruiting

Friedreich AtaxiaActive, not recruiting

Premature BirthPhase 2

Active, not recruiting

Blood TransfusionPreclinical

Unknown

HIV InfectionPreclinical

Unknown

NeutropeniaPhase 1

Active, not recruiting

Cardiac ArrestPhase 3

Active, not recruiting

Cerebral PalsyPreclinical

Active, not recruiting

Liver TransplantPhase 1

Active, not recruiting

Lung CancerPhase 3

Active, not recruiting

StrokePhase 2

Active, not recruiting

Friedreich AtaxiaPhase 2

Active, not recruiting

Showing 10 of 48 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Approved

4 2

Halaven

Eisai

Preclinical

38 3

MS Contin

Merck & Co.

Preclinical

2 4

Adenocard

Astellas

Preclinical

1 5

Zolymbus

AbbVie

Preclinical

1 6

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 7

Tricor

JJagotec

Preclinical

1 8

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 9

Paracetamol

GSK

Preclinical

1 10

Aquasol E

NNational Eye Institute (NEI)

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Myelodysplastic Syndrome

NCT00843882

Q3 2027

Phase 3Active, not recruiting

Myelodysplastic Syndromes

NCT03682536

Q4 2027

Phase 2Not yet recruiting

Anemia

NCT07463820

Q2 2029

Phase 2Recruiting

Acute Myeloid Leukemia

NCT05564390

Clinical

Trials by Indication[1]

Anemia52 trials

Treatment of Chronic Anemia With Epoetin Alfa in Elderly

Unknown status·RResearch and Education Foundation of Michael Reese Hospital·Phase 2·NCT00337441·62 enrolled

Epoetin Alfa for Anemia in Patients With Cancer Receiving Non-platinum Chemotherapy

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00270127·375 enrolled

A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of Subcutaneous Doses of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy

Completed·OOrtho Pharmaceuticals·N/A·NCT00002073

Show 49 more trials

A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy

Completed·OOrtho Pharmaceuticals·N/A·NCT00002071

The Safety and Effectiveness of r-HuEPO in Patients With AIDS and Anemia Caused by AIDS and Treatment With AZT

Completed·OOrtho Pharmaceuticals·N/A·NCT00002302

Survey on the Treatment of Anemia Using Recombinant Human Erythropoietin 2 (STAR-2)

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT00398749·1,927 enrolled

A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Completed· Roche logo

Roche·Phase 3·NCT00560404·233 enrolled

EPO-BUL-01 - Study of the Optimization of Anemia Management of EPREX (Epoetin Alfa) in Predialysis Patients With Chronic Renal Failure

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 4·NCT00338000·292 enrolled

Treatment of Anemia in Diabetic Subjects With CKD

Terminated· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00240734·11 enrolled

Alternate Dosing of PROCRIT (Epoetin Alfa) in Patients With Cancer and Chemotherapy Induced Anemia

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00338299·51 enrolled

A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia as a Result of Cancer Treatment With Cisplatin, a Platinum-containing Chemotherapy Drug

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00269997·72 enrolled

Erythropoietin Alfa in Elderly Subjects With Unexplained Anemia

Withdrawn·SStanford University·N/A·NCT00954486

A Study of Subcutaneous Mircera for the Treatment of Anemia in Peritoneal Dialysis Patients.

Terminated· Roche logo

Roche·Phase 3·NCT00442416·80 enrolled

Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants

Completed·KKyntra Bio·Phase 3·NCT02052310·1,043 enrolled

A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Children With Cancer Undergoing Chemotherapy

Completed·OOrtho Biotech Products, L.P.·Phase 3·NCT00261677·224 enrolled

Alternate Dosing - Initiation of Every 2 Week Epoetin Alfa (PROCRIT) in the Treatment of Anemia.

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00210743·67 enrolled

Epoetin Alfa (Hemax®) Phase IV Study in Chemotherapy Induced Anemia

Completed·BBio Sidus SA·Phase 4·NCT01374373·30 enrolled

Hemoglobin Optimization to Prevent Transfusion and Adverse Events in Perioperative Patients With Iron Restricted Anemia

Terminated·UUnity Health Toronto·Phase 2·NCT03528564·4 enrolled

A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in Patients With Anemia as a Result of Advanced Cancer and Treatment With Aggressive Chemotherapy

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00266617·86 enrolled

A Study to Determine the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia Caused by Advanced Cancer

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00269984·56 enrolled

RAPID-2. A Study to Evaluate the Effectiveness of Alternate Dosing of PROCRIT (Epoetin Alfa) in Maintaining Hemoglobin Levels in Patients With Chemotherapy Related Anemia

Terminated·OOrtho Biotech Products, L.P.·Phase 4·NCT00495378·25 enrolled

A Phase II Study to Assess Changes in Physical Function in Elderly Patients With Chronic Anemia

Terminated· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00210795·12 enrolled

Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer

Completed·JJonsson Comprehensive Cancer Center·Phase 2·NCT00255749·89 enrolled

Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy

Completed·MMayo Clinic·Phase 2·NCT00416624·239 enrolled

Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy

Completed·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00003600·344 enrolled

A Study to Evaluate the Hematologic Response Rate (the Rate at Which the Hemoglobin Level Rises) of PROCRIT (Epoetin Alfa) Given at a Dose of 80,000 Units Once Weekly to Cancer Patients With Anemia Who Are Receiving Chemotherapy.

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00341055·69 enrolled

Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer

Completed·JJonsson Comprehensive Cancer Center·Phase 3·NCT00070382·14 enrolled

Idiopathic Anemia of Aging (IAA)

Terminated·NNational Institute on Aging (NIA)·Phase 2·NCT00104169

A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in AIDS Patients With Anemia Caused Both by Their Disease and by AZT (Zidovudine, an Antiviral Drug) Given as Treatment for Their Disease

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00269945·60 enrolled

Treatment of Anemia in Patients With Cancer Who Are Not Currently Receiving Chemotherapy or Radiotherapy

Terminated· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00083486

Cost-effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients With Cancer Who Have Anemia

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT00264108·492 enrolled

A Study of Intravenous Mircera (C.E.R.A or Methoxy Polyethylene Glycol-epoetin Beta) for the Maintenance Treatment of Hemodialysis Participants With Chronic Renal Anemia

Completed· Roche logo

Roche·Phase 3·NCT00605293·101 enrolled

Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis

Unknown status· Jiangsu Hansoh Pharmaceutical Co., Ltd. logo

Jiangsu Hansoh Pharmaceutical Co., Ltd.·Phase 2·NCT02586402·60 enrolled

Epoetin Alfa in Treating Anemia in Patients With Solid Tumors

Completed·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00058331·365 enrolled

Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis

Completed· Astellas logo

Astellas·Phase 3·NCT02278341·838 enrolled

A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A MyeloMATCH Treatment Trial)

Not yet recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT07463820·270 enrolled

A Study of the Safety and Efficacy of Long-term Correction of Anemia With Epoetin Alfa in Early Hemodialysis Patients

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00261521·596 enrolled

Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa

Completed·AAkebia Therapeutics·Phase 2·NCT03799627·175 enrolled

Evaluate the Efficacy and Safety of HIF-PHI for the Treatment of Anemia and Risks of Cardiovascular and Cerebrovascular Events in ESRD Newly Initiated Dialysis Patients

Unknown status·SSecond Xiangya Hospital of Central South University·Phase 4·NCT04134026·400 enrolled

A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS and Advanced ARC Patients With Anemia

Completed·OOrtho Pharmaceuticals·N/A·NCT00002042

Desidustat in the Treatment of Anemia in CKD on Dialysis Patients

Completed·ZZydus Lifesciences Limited·Phase 3·NCT04215120·392 enrolled

Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis

Completed·KKyntra Bio·Phase 3·NCT02273726·741 enrolled

A Study to Assess the Response Rate of PROCRIT (Epoetin Alfa) Given at a Dose of 40,000 Units Once a Week to Cancer Patients With Anemia Who Are Not Receiving Chemotherapy.

Terminated·OOrtho Biotech Products, L.P.·Phase 3·NCT00350090·98 enrolled

The Benefits of a Preoperative Anemia Management Program

Terminated·UUniversity of Alabama at Birmingham·N/A·NCT01888003·51 enrolled

Treatment Program for Anemia in AIDS Patients

Completed·—·N/A·NCT00002022

A Phase II Study to Assess Changes in Physical Function in Elderly Patients With Chronic Anemia

Terminated· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00228995·9 enrolled

Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer

Unknown status·SSt. Bartholomew's Hospital·Phase 3·NCT00482716·80 enrolled

Cost Comparison Study of Darbepoetin Versus Epoetin Therapy to Treat Anemia in Hemodialysis Patients

Completed·AAndrea L Woodland·Phase 4·NCT02817555·50 enrolled

A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy

Completed·OOrtho Pharmaceuticals·N/A·NCT00002072

The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00270166·201 enrolled

Safety & Efficacy of Peginesatide for Treatment of Anemia in Participants on Dialysis Not Receiving an ESA

Completed·AAffymax·Phase 2·NCT00680043·114 enrolled

Research Into the Treatment of Anemia for Critically Ill Patients Admitted to Intensive Care Units (ICU)

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00091910·1,460 enrolled

Chronic Kidney Disease16 trials

A Study of the Use of PROCRIT (Epoetin Alfa) for the Treatment of Anemia in People With Chronic Kidney Disease Who Live in Long-term Care Facilities.

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00337935·157 enrolled

A Dose Conversion Study of Epoetin Alfa in Subjects With the Anemia of Chronic Kidney Disease.

Terminated·OOrtho Biotech Products, L.P.·Phase 4·NCT00495365·8 enrolled

A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia

Completed· Roche logo

Roche·Phase 3·NCT00090753·1,228 enrolled

Show 13 more trials

A Study to Evaluate PROCRIT (Epoetin Alfa) for Maintenance Phase Treatment of Patients With Anemia Due to Chronic Kidney Disease (PROMPT)

Completed·OOrtho Biotech Products, L.P.·Phase 2·NCT00307814·519 enrolled

A Study Comparing Mircera and Epoetin Alfa for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.

Terminated· Roche logo

Roche·Phase 3·NCT00422513·260 enrolled

Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis

Completed· Amgen logo

Amgen·Phase 4·NCT02253654·216 enrolled

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis.

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT02174731·2,133 enrolled

Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents

Terminated·AAkebia Therapeutics·Phase 2·NCT03140722·2 enrolled

A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)

Completed· Roche logo

Roche·Phase 4·NCT00773513·2,825 enrolled

Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis

Completed·AAffymax·Phase 3·NCT00597753·803 enrolled

FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease

Completed·KKyntra Bio·Phase 3·NCT02652806·305 enrolled

Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease

Completed·AAkebia Therapeutics·Phase 1·NCT03992066·46 enrolled

An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00440557·375 enrolled

A Study to Determine the Pharmacokinetic and Pharmacodynamic Profiles of PROCRIT (Epoetin Alfa) in Anemic Patients With Chronic Kidney Disease

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT00641589·40 enrolled

Anemia Study in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Blood Pressure (ASCEND-BP)

Completed· GSK logo

GSK·Phase 2·NCT03029247·105 enrolled

A Study of Four Dosing Regimens of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease. Protocol Addendum: Extension Study of Maintenance Therapy of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease.

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00212875·267 enrolled

Myelodysplastic Syndromes8 trials

An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01381809·130 enrolled

A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion

Terminated· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00695396·25 enrolled

LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS)

Terminated· Novartis logo

Novartis·Phase 2·NCT01034657·34 enrolled

Show 5 more trials

A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes

Withdrawn· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT06581055

A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

Withdrawn· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00446602

A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT03682536·363 enrolled

A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

Recruiting· Takeda logo

Takeda·Phase 3·NCT07422480·300 enrolled

A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate-Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-Naive Participants Who Are Non-Transfusion Dependent (NTD): The "ELEMENT-MDS" Trial

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT05949684·402 enrolled

Effectiveness7 trials

A Study to Evaluate the Effectiveness and Safety of Epoetin Alfa During the Period When One is Donating One's Own Blood Before Surgery.

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00270179·17 enrolled

A Study to Determine the Safety and Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Patients Who Are Not Anemic and Who Will be Undergoing Orthopedic or Heart and Blood Vessel Surgery

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2/3·NCT00270075·80 enrolled

The Safety and Effectiveness of r-HuEPO in Patients With AIDS or Advanced AIDS-Related Complex (ARC) Who Are Anemic

Completed·OOrtho Pharmaceuticals·N/A·NCT00002303

Show 4 more trials

A Study to Assess the Effectiveness of PROCRIT (Epoetin Alfa) Dosing Every 2 Weeks Versus Once a Week in Anemic HIV-infected Patients

Terminated· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00246298·31 enrolled

A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Facilitating the Presurgical Collection of Blood to be Used for Self-donation During Surgery on the Spine, Hip, or Knee.

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00270140·17 enrolled

A Study to Evaluate the Safety of Epoetin Alfa and Its Effectiveness in Facilitating the Presurgical Collection of Blood From Anemic Patients for Possible Self-transfusion During and After Scheduled Joint Surgery.

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00270062·77 enrolled

The Safety and Effectiveness of PROCRIT (Epoetin Alfa) in Patients Undergoing Elective Major Abdominal and/or Pelvic Surgery

Terminated· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 4·NCT00350519·37 enrolled

Efficacy and Safety5 trials

Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing a Treatment Plan of Preoperative Chemotherapy and Radiation Therapy, Followed by Surgery

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00036400·60 enrolled

An Efficacy and Safety Study of Epoetin Alfa (PROCRIT) Initiated at 40,000 Units Every Week Versus 80,000 Units Every Two Weeks in Anemic Patients With Cancer Receiving Chemotherapy.

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00210834·310 enrolled

An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Three Weeks

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00338416·115 enrolled

Show 2 more trials

An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Week or Every Four Weeks

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00337948·129 enrolled

An Efficacy and Safety Study for Epoetin Alfa (PROCRIT) in Cancer Patients Not Receiving Chemotherapy or Radiation

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00210587·51 enrolled

48 more indications

Blood Transfusion4 trials

A Study of the Safety and Effectiveness of Epoetin Alfa on Hemoglobin Levels and Blood Transfusions in Cancer Patients Receiving Chemotherapy

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 4·NCT00216541·110 enrolled

A Study to Determine the Safety of Epoetin Alfa and Whether Epoetin Alfa Can Reduce the Need for Blood Transfusions in Patients After Major Orthopedic Surgery.

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00270036·1 enrolled

A Study to Evaluate the Safety and Efficacy of Epoetin Alfa Versus Placebo to Reduce the Need for Blood Transfusions and Reduce the Occurrence of Severe Anemia During the Time Period Surrounding Total Hip Replacement Surgery

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT00269958·208 enrolled

Show 1 more trial

A Study to Determine Whether Epoetin Alfa Can Reduce the Need for Blood Transfusions in Patients During the Period of Time Around Major Orthopedic Surgery.

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00270088·316 enrolled

Breast Cancer4 trials

A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast Cancer

Terminated·OOrtho Biotech Products, L.P.·Phase 3·NCT00246597·37 enrolled

A Study to Evaluate the Impact of Maintaining Hemoglobin Levels Using Epoetin Alfa in Patients With Metastatic Breast Cancer Receiving Chemotherapy

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00211133·939 enrolled

Epoetin Alfa in Treating Chemotherapy-Related Anemia in Women With Stage I, Stage II, or Stage III Breast Cancer

Completed·JJonsson Comprehensive Cancer Center·Phase 4·NCT00022386

Show 1 more trial

Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer

Completed·NNCIC Clinical Trials Group·Phase 3·NCT00014222·2,104 enrolled

Intravenous Administration4 trials

PK and PD Parallel Study After Multiple Dose, Intravenous Administration of Two Epoetin Alfa, Eritromax and Eprex, in Healthy Subjects.

Unknown status·AAzidus Brasil·Phase 1·NCT01664221·80 enrolled

PK and PD Study After Single Dose, Intravenous Administration of Two Epoetin Alfa, Eritromax and Eprex, in Healthy Subjects

Unknown status·AAzidus Brasil·Phase 1·NCT01664195·28 enrolled

PK and PD Parallel Study After Multiple Dose, Intravenous Administration of Two Epoetin Alfa, Human Recombinant

Completed·AAzidus Brasil·Phase 1·NCT01685359·80 enrolled

Show 1 more trial

PK and PD Crossover Study After Single Dose, Intravenous Administration of Two Epoetin Alfa, Human Recombinant Epoetin and Eprex, in Healthy Subjects.

Completed·AAzidus Brasil·Phase 1·NCT01685333·28 enrolled

Chemotherapy3 trials

A Study of PROCRIT (Epoetin Alfa) 80,000 Units (U) Once Every Four Weeks (Q4W) vs. 40,000 U Once Every Two Weeks (Q2W) in Cancer Patients Not Receiving Chemotherapy

Terminated· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00306267·61 enrolled

A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy

Terminated· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00386152·235 enrolled

Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy

Terminated· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00083434

Fatigue3 trials

Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue

Completed·NNorthwestern University·Phase 2·NCT00004914

Epoetin Alfa in Treating Fatigue in Patients With Advanced Solid Tumors Who Are Not Receiving Chemotherapy

Withdrawn·MM.D. Anderson Cancer Center·N/A·NCT00052221

Randomized, Double-blind, Placebo-controlled Study to Assess Fatigue in Patients With ACD Due to RA Receiving PROCRIT

Terminated· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00236678·29 enrolled

Quality of Life3 trials

Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy

Completed·OOrtho Biotech, Inc.·Phase 4·NCT00524407·273 enrolled

The Effect of Epoetin Alfa on Cardiac Function and Quality of Life in Patients With Early Renal ((Kidney) Disease

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT00446576·176 enrolled

An Open-Label Study to Evaluate the Effect of Every Other Week PROCRIT� (Epoetin Alfa) Dosing (40,000-60,000 Units) On Maintaining Quality of Life and Target Hemoglobin Levels in Anemic HIV-Infected Patients (CHAMPS II)

Completed·OOrtho Biotech Products, L.P.·Phase 4·NCT00317902·292 enrolled

Myelodysplastic Syndrome3 trials

Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome

Completed·FFallon Clinic·Phase 2·NCT00053001

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT00843882·247 enrolled

Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome

Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00003681·50 enrolled

Immunodeficiency3 trials

A Study to Evaluate the Safety and Efficacy of Epoetin Alfa Versus Placebo for the Treatment of Anemia in Patients With Acquired Immunodeficiency Syndrome (AIDS) Who Are Receiving Zidovudine (AZT) Therapy

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00270283·102 enrolled

A Study to Evaluate the Safety and Efficacy of Epoetin Alfa Versus Placebo for the Treatment of Anemia in AIDS (Acquired Immunodeficiency Syndrome) Patients With Anemia Caused by the Disease and by Zidovudine (AZT) Therapy

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00270270·63 enrolled

A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in AIDS (Acquired Immunodeficiency Syndrome) Patients With Anemia Caused Both by Their Disease and by AZT (Zidovudine, an Antiviral Drug) Given as Treatment for Their Disease

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00270010·72 enrolled

Chronic Lymphocytic Leukemia2 trials

Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00270049·195 enrolled

Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy

Completed·MMemorial Sloan Kettering Cancer Center·Phase 3·NCT00003341·275 enrolled

Non-Small Cell Lung Cancer2 trials

Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20)

Terminated·OOntario Clinical Oncology Group (OCOG)·Phase 3·NCT00310232·70 enrolled

Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer

Completed·WWake Forest University Health Sciences·Phase 3·NCT00028938·1 enrolled

Prostate Cancer2 trials

Impact of Erythropoietin Treatment Versus Placebo on Quality-of-life in Patients With Advanced Prostate Cancer.

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT00364455·56 enrolled

Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00060398·282 enrolled

Safety and Efficacy2 trials

A Study to Confirm the Safety and Efficacy of Epoetin Alfa (PROCRIT) Administered Perioperatively vs. the Standard of Care in Blood Conservation in Patients Undergoing Major Elective Spinal Surgery (SPINE Study)

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00211146·680 enrolled

A Safety and Efficacy Study for Epoetin Alfa in Pre-dialysis Subjects.

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT00364260·172 enrolled

Renal insufficiency2 trials

Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR)

Terminated· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 4·NCT00211120·1,432 enrolled

Effects of Early Correction of Anemia in Patients With Chronic Renal Insufficiency

Terminated· Johnson & Johnson logo

Johnson & Johnson·Phase 4·NCT00312871·217 enrolled

Head and Neck Cancer2 trials

Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 3·NCT00004917

Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Head and Neck Cancer

Terminated·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00017277·47 enrolled

End-Stage Renal Disease2 trials

Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China

Completed·KKyntra Bio·Phase 2·NCT01596855·96 enrolled

Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis

Completed·KKyntra Bio·Phase 2·NCT01147666·161 enrolled

Hemoglobin2 trials

A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.

Terminated· Roche logo

Roche·Phase 3·NCT00454246·111 enrolled

PROCRIT Extended Dosing For Maintenance of Hemoglobin in Pre-Dialysis CKD Patients

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00440466·430 enrolled

Erythropoietin2 trials

A Study of Granulocyte Colony-Stimulating Factor Plus Recombinant Erythropoietin Plus Zidovudine in Patients With AIDS or AIDS-Related Complex

Completed· Amgen logo

Amgen·N/A·NCT00002281·24 enrolled

Impact of Erythropoietin on Hematological Adaptations and Physical Performance

Completed·—·Phase 4·NCT05078138·8 enrolled

Multiple Myeloma2 trials

Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma

Completed·TThe Cleveland Clinic·N/A·NCT00400686·31 enrolled

The Effect of Epoetin Alfa on the Anemia of Patients With Multiple Myeloma

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00270101·156 enrolled

Orthopedic Surgery2 trials

PROCRIT and Short-Term Outcomes in Orthopedic Surgery

Terminated· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00236405·6 enrolled

A Study of the Safety and Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Patients Who Are Undergoing Orthopedic Surgery and Who Have Low Hematocrit Levels (the Percent of Red Blood Cells in Whole Blood)

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2/3·NCT00270114·55 enrolled

Exercise1 trial

Effects of Exercise in Combination With Epoetin Alfa

Completed·UUniversity of Arkansas·N/A·NCT00577096·120 enrolled

Ataxia1 trial

Efficacy of Epoetin Alfa in Patients With Friedreich's Ataxia

Completed·FFederico II University·Phase 2·NCT00631202·10 enrolled

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 4·NCT00283465·316 enrolled

Hip Replacement Surgery1 trial

A Study to Determine an Effective Dose of Epoetin Alfa to Decrease the Number of Units of Blood Required to be Transfused During Hip Replacement Surgery.

Withdrawn· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT00269971

Cognition1 trial

Treatment With Erythropoietin and Cognition During Hypoglycaemia

Completed·HHillerod Hospital, Denmark·N/A·NCT00615368·11 enrolled

Blood Loss During Surgery1 trial

A Study to Determine the Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Non-anemic Patients Who Are Undergoing Orthopedic, Heart and Blood Vessel, or Breast Reduction Surgery; Performed in Combination With a Procedure to Reduce Blood Loss During Surgery.

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2/3·NCT00270023·112 enrolled

Radiation Therapy1 trial

PROCRIT (Epoetin Alfa) 60,000 Units Administered Once Every Two Weeks in Anemic Cancer Patients Who Are Not Receiving Chemotherapy or Radiation Therapy

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00388336·57 enrolled

Kidney Transplant1 trial

Study of Epoetin Alfa to Treat Anemia After Kidney Transplantation

Terminated·—·N/A·NCT01290328·100 enrolled

Friedreich ataxia1 trial

Efficacy Study of Epoetin Alfa in Friedreich Ataxia

Completed·FFederico II University·Phase 2·NCT01493973·56 enrolled

Cervical Cancer1 trial

Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia

Completed·GGynecologic Oncology Group·Phase 3·NCT00017004·114 enrolled

Kidney Disease1 trial

A Study to Assess Disability in Anemic Elderly Patients With Kidney Disease Receiving PROCRIT (Epoetin Alfa)

Terminated·OOrtho Biotech Products, L.P.·Phase 4·NCT00338468·13 enrolled

Brain Injury1 trial

Erythropoietin in Traumatic Brain Injury (EPO-TBI)

Completed·—·Phase 3·NCT00987454·606 enrolled

Delayed Graft Function1 trial

Effect of Procrit (Epoetin Alfa) on Preventing Delayed Graft Function After Deceased Donor Renal Transplantation

Completed·WWest Penn Allegheny Health System·Phase 4·NCT00425126·76 enrolled

Thalassemia1 trial

Phase II Study of Arginine Butyrate With or Without Epoetin Alfa in Patients With Thalassemia Intermedia

Completed·—·Phase 2·NCT00006136·15 enrolled

Acute Myocardial Infarction1 trial

Clinical Study to Examine the Effects of Erythropoietin on Left Ventricular Function After Acute Myocardial Infarction

Completed·UUniversity Medical Center Groningen·Phase 2·NCT00449488·529 enrolled

Randomized1 trial

Cross Iron (Comparative Randomized Oral Versus Systemic IRON)

Completed·UUniversity Hospital, Montpellier·N/A·NCT02496377·100 enrolled

Granulocyte Colony Stimulating Factor1 trial

An Open-Label Phase I/II Study of Recombinant Granulocyte Colony Stimulating Factor (r-metHuG-CSF) and Recombinant Erythropoietin (rHuEPO) Given Subcutaneously Along With Zidovudine (AZT) to Patients With the Acquired Immune Deficiency Syndrome (AIDS) or Severe AIDS-Related Complex (ARC)

Completed· Amgen logo

Amgen·Phase 1·NCT00002255

Pancreatic Cancer1 trial

Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00049348

Encephalopathy1 trial

PAEAN - Erythropoietin for Hypoxic Ischaemic Encephalopathy in Newborns

Completed·UUniversity of Sydney·Phase 3·NCT03079167·313 enrolled

Myocardial Infarction1 trial

REVEAL: Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction

Completed·NNational Institute on Aging (NIA)·Phase 2·NCT00378352·223 enrolled

Neutropenia1 trial

Peripheral Stem Cell Transplantation to Prevent Neutropenia in Patients Receiving Chemotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma

Terminated·NNorthwestern University·Phase 1·NCT00005787·3 enrolled

Critically Ill Patients1 trial

Pharmacokinetic/ Pharmacodynamic Study of Epoetin Alfa (PROCRIT) in Critically Ill Patients.

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00210756·60 enrolled

Subarachnoid Hemorrhage1 trial

Treating Patients With Aneurysmal SubArachnoid Hemorrhage (SAH) With Epoetin Alfa

Terminated·UUniversity of South Florida·Phase 4·NCT00626574·3 enrolled

Hemodialysis1 trial

Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis

Terminated· Amgen logo

Amgen·Phase 4·NCT01737879·41 enrolled

Rheumatoid Arthritis1 trial

Open-Label Extension Safety Study of PROCRIT in Patients With Anemia of Chronic Disease Due to Rheumatoid Arthritis

Withdrawn·OOrtho Biotech Products, L.P.·Phase 2·NCT00123149

Acute Myeloid Leukemia1 trial

Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT05564390·2,000 enrolled

Unspecified3 trials

Generation of Positive Biological Samples to Epoetin for Doping Control.

Completed·PParc de Salut Mar·Phase 1·NCT02920372·2 enrolled

The Effect of PROCRIT (Epoetin Alfa) on Postoperative Vigor and Handgrip Strength (VIGOR Study)

Completed·OOrtho Biotech, Inc.·Phase 4·NCT00401869·289 enrolled

The Duration Study

Terminated· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00210730·2 enrolled

Sources

References

[1]
ClinicalTrials.gov — 168 trial records for Epoetin Alfa. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Epogen drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Epoetin Alfa compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Epoetin Alfa. EMBL-EBI & Wellcome Sanger Institute.
[5]
SEC EDGAR — Johnson & Johnson Pharmaceutical Research & Development, L.L.C. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Erythropoietin Receptor Agonist[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Epogen

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Q4 2027

Q2 2029

Trials by Indication[1]

Anemia52 trials

Chronic Kidney Disease16 trials

Myelodysplastic Syndromes8 trials

Effectiveness7 trials

Efficacy and Safety5 trials

Blood Transfusion4 trials

Breast Cancer4 trials

Intravenous Administration4 trials

Chemotherapy3 trials

Fatigue3 trials

Quality of Life3 trials

Myelodysplastic Syndrome3 trials

Immunodeficiency3 trials

Chronic Lymphocytic Leukemia2 trials

Non-Small Cell Lung Cancer2 trials

Prostate Cancer2 trials

Safety and Efficacy2 trials

Renal insufficiency2 trials

Head and Neck Cancer2 trials

End-Stage Renal Disease2 trials

Hemoglobin2 trials

Erythropoietin2 trials

Multiple Myeloma2 trials

Orthopedic Surgery2 trials

Exercise1 trial

Ataxia1 trial

Liver Transplant1 trial

Neuropathy1 trial

Red Blood Cell Transfusions1 trial

Hip Replacement Surgery1 trial

Cognition1 trial

Blood Loss During Surgery1 trial

Radiation Therapy1 trial

Kidney Transplant1 trial

Friedreich ataxia1 trial

Cervical Cancer1 trial

Kidney Disease1 trial

Brain Injury1 trial

Delayed Graft Function1 trial

Thalassemia1 trial

Acute Myocardial Infarction1 trial

Randomized1 trial

Granulocyte Colony Stimulating Factor1 trial

Pancreatic Cancer1 trial

Encephalopathy1 trial

Myocardial Infarction1 trial

Neutropenia1 trial

Critically Ill Patients1 trial

Subarachnoid Hemorrhage1 trial

Hemodialysis1 trial

Rheumatoid Arthritis1 trial

Acute Myeloid Leukemia1 trial

Unspecified3 trials

References

Drug Info

Quick Facts

Related News